Engineered T Cell Therapy for Cancer in the Clinic

Engineered T Cell Therapy for Cancer in the Clinic

T cells play a key role in cell-mediated immunity, and strategies to genetically modify T cells, including chimeric antigen receptor (CAR) T cell therapy and T cell receptor (TCR) T cell therapy, have achieved substantial advances in the treatment of malignant tumors. In clinical trials, CAR-T cell...

Full description

Bibliographic Details
Main Authors: Lijun Zhao, Yu J. Cao
Format: Article
Language:English
Published: Frontiers Media S.A. 2019-10-01
Series:Frontiers in Immunology
Subjects:
engineered T cells
CAR-T cell
TCR-T cell
clinic
immunotherapy
Online Access:https://www.frontiersin.org/article/10.3389/fimmu.2019.02250/full
id doaj-1885fa40dea34a94a49d04103d9673fd
record_format Article
spelling doaj-1885fa40dea34a94a49d04103d9673fd2020-11-25T02:15:02ZengFrontiers Media S.A.Frontiers in Immunology1664-32242019-10-011010.3389/fimmu.2019.02250484029Engineered T Cell Therapy for Cancer in the ClinicLijun ZhaoYu J. CaoT cells play a key role in cell-mediated immunity, and strategies to genetically modify T cells, including chimeric antigen receptor (CAR) T cell therapy and T cell receptor (TCR) T cell therapy, have achieved substantial advances in the treatment of malignant tumors. In clinical trials, CAR-T cell and TCR-T cell therapies have produced encouraging clinical outcomes, thereby demonstrating their therapeutic potential in mitigating tumor development. This article summarizes the current applications of CAR-T cell and TCR-T cell therapies in clinical trials worldwide. It is predicted that genetically engineered T cell immunotherapies will become safe, well-tolerated, and effective therapeutics and bring hope to cancer patients.https://www.frontiersin.org/article/10.3389/fimmu.2019.02250/fullengineered T cellsCAR-T cellTCR-T cellclinicimmunotherapy
collection DOAJ
language English
format Article
sources DOAJ
author Lijun Zhao
Yu J. Cao
spellingShingle Lijun Zhao
Yu J. Cao
Engineered T Cell Therapy for Cancer in the Clinic
Frontiers in Immunology
engineered T cells
CAR-T cell
TCR-T cell
clinic
immunotherapy
author_facet Lijun Zhao
Yu J. Cao
author_sort Lijun Zhao
title Engineered T Cell Therapy for Cancer in the Clinic
title_short Engineered T Cell Therapy for Cancer in the Clinic
title_full Engineered T Cell Therapy for Cancer in the Clinic
title_fullStr Engineered T Cell Therapy for Cancer in the Clinic
title_full_unstemmed Engineered T Cell Therapy for Cancer in the Clinic
title_sort engineered t cell therapy for cancer in the clinic
publisher Frontiers Media S.A.
series Frontiers in Immunology
issn 1664-3224
publishDate 2019-10-01
description T cells play a key role in cell-mediated immunity, and strategies to genetically modify T cells, including chimeric antigen receptor (CAR) T cell therapy and T cell receptor (TCR) T cell therapy, have achieved substantial advances in the treatment of malignant tumors. In clinical trials, CAR-T cell and TCR-T cell therapies have produced encouraging clinical outcomes, thereby demonstrating their therapeutic potential in mitigating tumor development. This article summarizes the current applications of CAR-T cell and TCR-T cell therapies in clinical trials worldwide. It is predicted that genetically engineered T cell immunotherapies will become safe, well-tolerated, and effective therapeutics and bring hope to cancer patients.
topic engineered T cells
CAR-T cell
TCR-T cell
clinic
immunotherapy
url https://www.frontiersin.org/article/10.3389/fimmu.2019.02250/full
work_keys_str_mv AT lijunzhao engineeredtcelltherapyforcancerintheclinic
AT yujcao engineeredtcelltherapyforcancerintheclinic
_version_ 1724898278655393792

Similar Items